Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States

The study sample included 11,551 patients, with 9,106 receiving liraglutide and 2,445 receiving exenatide once weekly.

• Exenatide QW patients had statistically significantly lower odds of overall inpatient admissions (odds ratio = 0.80) compared to liraglutide patients.
• Lower odds of diabetes-specific inpatient admissions were also observed for exenatide QW patients (odds ratio = 0.83).
• Overall total healthcare costs were similar for both groups, with exenatide QW costing $7,833 and liraglutide costing $8,296.
• Exenatide QW was associated with statistically significantly lower overall medical costs ($3,939) compared to liraglutide ($4,652).
• Diabetes-specific medical costs were also lower for exenatide QW patients ($1,161) compared to liraglutide patients ($1,469).
• Exploratory analyses indicated exenatide QW patients had a greater median number of days supplied during follow-up (141 days) than liraglutide patients (124 days).

AI simplified